アテローム性動脈硬化症治療薬の世界市場レポート 2024

アテローム性動脈硬化症治療薬の市場規模は、今後数年間で着実に成長すると予想されています。 2028年には3.1%の年間複合成長率（CAGR）で570億3,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、新しい治療法の出現、精密医療の進歩、免疫療法と炎症への注目、脂質管理の革新、および規制の支援によるものと考えられます。予測期間中に予測される主な動向には、生物学的療法の利用、遺伝子編集と遺伝子治療の実施、併用療法の採用、個別化された治療アプローチ、遠隔医療と遠隔モニタリングの統合が含まれます。

アテローム性動脈硬化症治療薬市場の成長は、心血管疾患の有病率の増加によって促進されると予想されます。心血管疾患には、心臓と血管に影響を与えるさまざまな状態が含まれますが、特にアテローム性動脈硬化症は、動脈壁への脂肪、コレステロール、その他の物質の蓄積に関係します。動脈内のプラークの蓄積を特徴とするこの状態は、冠状動脈性心疾患や脳卒中などの心血管疾患の原因となります。 アテローム性動脈硬化症治療薬は、合併症のリスクを軽減し、コレステロール値の上昇や血栓の形成などの根本的な要因を管理することにより、心血管疾患の治療において重要な役割を果たします。たとえば、国家統計局が2022年 3月に発表した報告書によると、2020年から2021年の間に英国で19,440人から20,061人が心臓発作により死亡しました。さらに、2023年5月の疾病管理予防センターによると、米国の20歳以上の成人20人に1人が心血管疾患を患っており、2021年には69万5,000人がこれらの疾患に苦しみ、同年には37万5,476人が心血管疾患が原因で死亡したとされています。したがって、心血管疾患の蔓延がアテローム性動脈硬化症治療薬市場を牽引すると予想されます。

アテローム性動脈硬化症治療薬市場の成長は、高齢化人口の増加によって促進されると予想されます。高齢化人口とは、社会内で高齢者または高齢者とみなされる個人の割合または数の大幅な増加を特徴とする人口動態の変化を指します。 アテローム性動脈硬化症治療薬は、高齢化社会における心血管リスクの上昇に対処する上で重要な役割を果たし、全体的な健康のための予防、管理、治療に貢献します。たとえば、2023年 6月の時点で、米国国勢調査局は、国の平均年齢が0.2年増加して2022年には38.9歳になると報告しており、人口の高齢化傾向が続いていることを示しています。したがって、高齢化人口の増加は、アテローム性動脈硬化症治療薬市場の成長の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のアテローム性動脈硬化症治療薬市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 抗血小板薬
• フィブリン酸とオメガ 3脂肪酸誘導体
• アンジオテンシン被覆酵素（ACE）阻害剤
• 利尿薬
• コレステロール低下薬
• ベータブロッカー
• カルシウムチャネルブロッカー
• 他の薬物クラス
• 世界のアテローム性動脈硬化症治療薬市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 経口
• 注射
• 世界のアテローム性動脈硬化症治療薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• オンライン薬局
• 小売薬局
• その他の流通チャネル

第7章 地域および国の分析

• 世界のアテローム性動脈硬化症治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界のアテローム性動脈硬化症治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 市場の競合情勢
• 市場企業プロファイル
  • Johnson And Johnson Private Limited
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • AbbVie Inc.
  • Bayer AG

第31章 その他の大手および革新的な企業

• Janssen Pharmaceuticals Inc.
• Novartis AG
• Merck And Co.Inc.
• Sanofi SA
• AstraZeneca plc
• Abbott Laboratories
• GSK plc.
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Novo Nordisk A/S
• Boehringer Ingelheim International GmbH
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Atherosclerosis drugs are medications employed for the management and treatment of atherosclerosis, a condition characterized by the accumulation of plaque in the arteries. The objectives of drug treatment for atherosclerosis include reducing plaque formation, slowing its progression, and addressing risk factors associated with the development of atherosclerosis.

The primary categories of atherosclerosis drugs encompass anti-platelet medications, fibric acid and omega-3 fatty acid derivatives, angiotensin-covering enzyme (ACE) inhibitors, diuretics, cholesterol-lowering medications, beta-blockers, calcium channel blockers, and other related medications. Antiplatelet medications are drugs that hinder the formation of blood clots by impeding the aggregation of platelets, which are small cell fragments in the blood. These drugs can be administered orally or through injections and are primarily dispensed through various channels, including hospital pharmacies, online pharmacies, retail pharmacies, and others.

The atherosclerosis drugs market research report is one of a series of new reports from The Business Research Company that provides atherosclerosis drugs market statistics, including atherosclerosis drugs industry global market size, regional shares, competitors with an atherosclerosis drugs market share, detailed atherosclerosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the atherosclerosis drugs industry. This atherosclerosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The atherosclerosis drugs market size has grown steadily in recent years. It will grow from $48.72 billion in 2023 to $50.5 billion in 2024 at a compound annual growth rate (CAGR) of 3.6%. The expansion observed in the historical period can be credited to efforts in cholesterol management, the control of blood pressure, the implementation of smoking cessation programs, research and development initiatives, and advancements in diagnostic technologies.

The atherosclerosis drugs market size is expected to see steady growth in the next few years. It will grow to $57.03 billion in 2028 at a compound annual growth rate (CAGR) of 3.1%. The anticipated growth in the forecast period can be ascribed to the emergence of new therapies, advancements in precision medicine, the focus on immunotherapy and inflammation, innovations in lipid management, and regulatory support. Key trends projected for the forecast period encompass the utilization of biologic therapies, the implementation of gene editing and gene therapy, the adoption of combination therapies, personalized treatment approaches, and the integration of telemedicine and remote monitoring.

The growth of the atherosclerosis drug market is expected to be propelled by the increasing prevalence of cardiovascular diseases. Cardiovascular diseases encompass a range of conditions affecting the heart and blood vessels, with atherosclerosis specifically involving the accumulation of fats, cholesterol, and other substances on artery walls. This condition, marked by plaque buildup inside the arteries, contributes to cardiovascular diseases such as coronary heart disease and stroke. Atherosclerosis drugs play a crucial role in treating cardiovascular diseases by reducing the risk of complications and managing underlying factors such as elevated cholesterol levels and the formation of blood clots. For example, a report published by The Office for National Statistics in March 2022 indicated that between 2020 and 2021, 19,440 to 20,061 people in the UK died due to heart attacks. Additionally, according to the Centers for Disease Control and Prevention in May 2023, 1 in 20 adults aged 20 and older in the US had cardiovascular diseases, with 695,000 people suffering from these conditions in 2021, and 375,476 deaths attributed to cardiovascular diseases that same year. Thus, the prevalence of cardiovascular diseases is expected to drive the atherosclerosis drug market.

The growth of the atherosclerosis drug market is anticipated to be fueled by the increasing aging population. The aging population refers to a demographic shift characterized by a significant rise in the proportion or number of individuals within a society who are considered elderly or senior citizens. Atherosclerosis drugs play a critical role in addressing elevated cardiovascular risks in the aging population, contributing to prevention, management, and treatment for overall well-being. For instance, as of June 2023, The United States Census Bureau reported a 0.2-year increase in the country's median age to 38.9 years in 2022, indicating a continued aging trend in the population. Consequently, the growing aging population is a driving force behind the growth of the atherosclerosis drug market.

Product innovation emerges as a prominent trend gaining momentum in the atherosclerosis drugs market. Major companies within the market are actively engaged in the development of innovative drugs and securing approvals as part of their strategy to maintain a strong market position. For example, in December 2021, Novartis AG, a pharmaceutical company based in Switzerland, obtained approval from the US Food and Drug Administration (FDA) for Leqvio (inclisiran), a groundbreaking siRNA designed to lower cholesterol and treat individuals with atherosclerotic cardiovascular disease. Administered through subcutaneous injection, this novel drug effectively reduces low-density lipoproteins (LDL) cholesterol levels in the bloodstream for adults with clinical atherosclerotic cardiovascular disease, offering a new treatment option for those unable to achieve their LDL cholesterol goals with existing therapies.

Major companies operating in the atherosclerosis drugs market are diversifying their product portfolios by introducing anti-inflammatory drugs to enhance market profitability. Anti-inflammatory drugs for atherosclerosis are specifically formulated to alleviate inflammation associated with the condition characterized by plaque buildup in arteries. For instance, AGEPHA Pharma, a European manufacturer of medical products, launched LODOCO. This drug, comprising colchicine in 0.5 mg tablets, received approval from the U.S. FDA as an innovative anti-inflammatory atheroprotective cardiovascular treatment. LODOCO has demonstrated efficacy in reducing the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with atherosclerotic disease or multiple cardiovascular risk factors. Addressing residual inflammation, a critical factor in atherosclerotic cardiovascular disease (ASCVD), LODOCO can be used alone or in combination with cholesterol-lowering medications, marking a significant breakthrough in cardiovascular care.

In April 2023, Chiesi Farmaceutici S.p.A., an Italian pharmaceutical company, completed the acquisition of Amryt Pharma plc for an approximate sum of $1.25 billion. This strategic move aims to expand Chiesi Farmaceutici S.p.A.'s rare disease portfolio, gain access to Amryt's pipeline of developmental candidates, and establish a presence in the US market. Amryt Pharma plc, based in Ireland, specializes in the development of atherosclerosis drugs for the treatment of rare diseases, including atherosclerosis and generalized lipodystrophies.

Major companies operating in the atherosclerosis drugs market report are Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co.Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc., Anthera Pharmaceuticals Inc

North America was the largest region in the atherosclerosis drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the atherosclerosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The atherosclerosis drugs market consists of sales of statins, rosuvastatin, atorvastatin, fibrates, bile acid sequestrants, nitrates, ezetimibe, and blood pressure medications. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Atherosclerosis Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on atherosclerosis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for atherosclerosis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The atherosclerosis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drug Class: Anti-Platelet Medications; Fibric Acid And Omega-3 Fatty Acid Derivatives; Angiotensin-Covering Enzyme (ACE) Inhibitors; Diuretics; Cholesterol Lowering Medication; Beta Blockers; Calcium Channel Blockers; Other Drug Classes
• 2) By Route Of Administration: Oral; Injectable
• 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies; Other Distribution Channels
• Companies Mentioned: Johnson And Johnson Private Limited; Pfizer Inc.; F. Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Atherosclerosis Drugs Market Characteristics

3. Atherosclerosis Drugs Market Trends And Strategies

4. Atherosclerosis Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Atherosclerosis Drugs Market Size and Growth

• 5.1. Global Atherosclerosis Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Atherosclerosis Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Atherosclerosis Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Atherosclerosis Drugs Market Segmentation

• 6.1. Global Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Anti-Platelet Medications
• Fibric Acid And Omega-3 Fatty Acid Derivatives
• Angiotensin-Covering Enzyme (ACE) Inhibitors
• Diuretics
• Cholesterol Lowering Medication
• Beta Blockers
• Calcium Channel Blockers
• Other Drug Classes
• 6.2. Global Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Injectable
• 6.3. Global Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Other Distribution Channels

7. Atherosclerosis Drugs Market Regional And Country Analysis

• 7.1. Global Atherosclerosis Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Atherosclerosis Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Atherosclerosis Drugs Market

• 8.1. Asia-Pacific Atherosclerosis Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Atherosclerosis Drugs Market

• 9.1. China Atherosclerosis Drugs Market Overview
• 9.2. China Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Atherosclerosis Drugs Market

• 10.1. India Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Atherosclerosis Drugs Market

• 11.1. Japan Atherosclerosis Drugs Market Overview
• 11.2. Japan Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Atherosclerosis Drugs Market

• 12.1. Australia Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Atherosclerosis Drugs Market

• 13.1. Indonesia Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Atherosclerosis Drugs Market

• 14.1. South Korea Atherosclerosis Drugs Market Overview
• 14.2. South Korea Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Atherosclerosis Drugs Market

• 15.1. Western Europe Atherosclerosis Drugs Market Overview
• 15.2. Western Europe Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Atherosclerosis Drugs Market

• 16.1. UK Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Atherosclerosis Drugs Market

• 17.1. Germany Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Atherosclerosis Drugs Market

• 18.1. France Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Atherosclerosis Drugs Market

• 19.1. Italy Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Atherosclerosis Drugs Market

• 20.1. Spain Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.15. Spain Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Atherosclerosis Drugs Market

• 21.1. Eastern Europe Atherosclerosis Drugs Market Overview
• 21.2. Eastern Europe Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Atherosclerosis Drugs Market

• 22.1. Russia Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Atherosclerosis Drugs Market

• 23.1. North America Atherosclerosis Drugs Market Overview
• 23.2. North America Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Atherosclerosis Drugs Market

• 24.1. USA Atherosclerosis Drugs Market Overview
• 24.2. USA Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Atherosclerosis Drugs Market

• 25.1. Canada Atherosclerosis Drugs Market Overview
• 25.2. Canada Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Atherosclerosis Drugs Market

• 26.1. South America Atherosclerosis Drugs Market Overview
• 26.2. South America Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Atherosclerosis Drugs Market

• 27.1. Brazil Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Atherosclerosis Drugs Market

• 28.1. Middle East Atherosclerosis Drugs Market Overview
• 28.2. Middle East Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Atherosclerosis Drugs Market

• 29.1. Africa Atherosclerosis Drugs Market Overview
• 29.2. Africa Atherosclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Atherosclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Atherosclerosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Atherosclerosis Drugs Market Competitive Landscape And Company Profiles

• 30.1. Atherosclerosis Drugs Market Competitive Landscape
• 30.2. Atherosclerosis Drugs Market Company Profiles
  • 30.2.1. Johnson And Johnson Private Limited
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Pfizer Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmann-La Roche AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. AbbVie Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bayer AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Atherosclerosis Drugs Market Other Major And Innovative Companies

• 31.1. Janssen Pharmaceuticals Inc.
• 31.2. Novartis AG
• 31.3. Merck And Co.Inc.
• 31.4. Sanofi S.A.
• 31.5. AstraZeneca plc
• 31.6. Abbott Laboratories
• 31.7. GSK plc.
• 31.8. Takeda Pharmaceutical Company Limited
• 31.9. Eli Lilly and Company
• 31.10. Gilead Sciences Inc.
• 31.11. Amgen Inc.
• 31.12. Novo Nordisk A/S
• 31.13. Boehringer Ingelheim International GmbH
• 31.14. Viatris Inc.
• 31.15. Teva Pharmaceutical Industries Ltd.

32. Global Atherosclerosis Drugs Market Competitive Benchmarking

33. Global Atherosclerosis Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Atherosclerosis Drugs Market

35. Atherosclerosis Drugs Market Future Outlook and Potential Analysis

• 35.1 Atherosclerosis Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Atherosclerosis Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Atherosclerosis Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer